避孕药市场按药丸类别、荷尔蒙成分、活性成分含量、黄体素生成、用户年龄层、处方状态、品牌类型、应用需求、包装类型、分销管道和地区划分

预计到 2025 年，避孕药具市场价值为 81.2 亿美元，到 2032 年将达到 131.2 亿美元，2025 年至 2032 年的复合年增长率为 7.1%。

全球避孕药市场是生殖健康产业的重要组成部分，其中包括口服避孕药。口服避孕药旨在透过调节荷尔蒙机制来预防意外怀孕。这些药物主要含有合成雌激素和黄体素，它们透过抑制排卵、改变子宫颈黏液的性状以及改变子宫内膜，从而形成多重受孕屏障。

自1960年代首款口服避孕药问世以来，市场发生了显着变化，从最初的基础荷尔蒙製剂发展到如今更先进、剂量更低的组合药物，在保持疗效的同时，最大限度地减少了副作用。现代避孕药分为复方製剂（含有雌激素和黄体素）和单方製剂（仅含有黄体素），每种製剂都为不同的患者群提供独特的益处。

该行业透过多种配方满足消费者的各种需求，包括单相、双相、三相、长週期避孕药和事后紧急避孕药。该市场在一个复杂的生态系统中运作，涉及製药企业、医疗保健机构、监管机构和终端用户，其通路涵盖医院、诊所、药房以及不断扩展的线上平台。避孕药市场持续推动医疗领域的创新，满足消费者对更便利、更少副作用和更强的非避孕治疗益处的不断变化的需求。

市场动态

全球避孕市场正经历强劲成长，这主要得益于几个相互关联的因素：政府主导的促进避孕措施普及和教育计画提高了人们对计划生育和生殖健康的认识，尤其是在发展中地区，这是市场扩张的主要驱动力。

全球女性劳动参与率的不断提高，催生了对可靠避孕方法的需求，使女性能够根据自身职业目标规划生育。同时，对女性赋权和生殖权利的日益重视，进一步加速了避孕方法的普及。许多国家医疗基础设施的改善和避孕药具保险覆盖范围的扩大，推动了市场渗透。此外，持续的产品创新，例如低剂量荷尔蒙和新的给药方式，透过减少副作用和改善用户体验，也为市场提供了支持。

然而，市场有许多限制，例如保守社会中对避孕药具使用的文化和宗教反对，这限制了某些地区的市场渗透率；此外，长期使用激素避孕药具的安全问题，包括血栓症、心血管併发症和情绪障碍风险增加，也让潜在用户和医疗保健提供者犹豫不决。

严格的避孕产品核准流程增加了研发成本和上市时间，而子宫内避孕器、植入和屏障避孕法等其他避孕方法的存在加剧了市场竞争。新兴市场中存在着巨大的机会，这些市场年轻人口不断增长，个人化荷尔蒙解决方案得益于新技术，避孕药在痤疮、子宫内膜异位症和卵巢症候群（PCOS）等疾病的治疗用途也日益广泛。这些因素扩大了潜在市场规模，并开启了新的收入来源。

本报告的主要特点

• 本报告对全球避孕药市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
• 根据公司概况、产品系列、主要亮点、财务表现和策略等参数，对全球避孕药具市场的主要企业进行了分析。
• 本报告提供的见解将使负责人和公司经营团队能够就未来的产品发布、产品更新、市场扩张和行销策略做出明智的决策。
• 《全球避孕药具市场》报告面向该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过各种用于分析全球避孕药具市场的策略矩阵，更轻鬆地做出决策。

目录

第一章 分析目标与先决条件

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监理及趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特五力分析
• 企业合併情景
• 产业趋势

4. 全球避孕药市场（按片剂类别划分）（2020-2032 年）

• 复方口服避孕药（COCs）
• 仅含黄体素的片剂（POP/迷你丸）
• 事后紧急避孕药（ECP）

5. 全球避孕药市场（依荷尔蒙配方划分）（2020-2032 年）

• 单相片剂
• 双相片剂
• 三相片

6. 全球避孕药市场依活性成分含量划分（2020-2032 年）

• 低剂量药片
• 标准剂量药片
• 高剂量药片

7. 全球避孕药市场（以黄体素代数划分）（2020-2032 年）

• 第一代黄体素片
• 第二代孕激素片
• 第三代黄体素片
• 第四代孕激素片

8. 全球避孕药具市场依使用者年龄层划分（2020-2032 年）

• 15至19岁
• 20-29岁
• 30-39岁
• 40岁或以上

9. 全球避孕药市场（依处方状态划分）（2020-2032 年）

• 处方笺药
• 非处方药

第十章 全球避孕药具市场（依品牌类型划分）（2020-2032 年）

• 非专利的
• 品牌药

第十一章 全球避孕市场依应用需求划分（2020-2032 年）

• 避孕
• 荷尔蒙调节
• 痤疮治疗
• 月经週期管理

第十二章 全球避孕药具市场按包装类型划分（2020-2032 年）

• 21天装
• 24天装
• 28 天装
• 91天装

13. 全球避孕药具市场按通路划分（2020-2032 年）

• 医院药房
• 零售药房
• 网路药房

第十四章 全球避孕药具市场（按地区划分）（2020-2032 年）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中非

第十五章 竞争格局

• Pfizer Inc
• Bayer AG
• Organon &Co
• Teva Pharmaceutical Industries Ltd
• Mylan NV（Viatris Inc）
• Johnson &Johnson
• Gedeon Richter Plc
• Lupin Limited
• Cipla Limited
• HLL Lifecare Limited
• Piramal Enterprises Limited
• Sun Pharmaceutical Industries Ltd
• Allergan plc（AbbVie Inc）
• Cadila Healthcare Ltd（Zydus Lifesciences）
• Torrent Pharmaceuticals Ltd

第十六章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map (COM)

第十七章 参考文献与分析方法

• 参考
• 分析方法
• 关于 Coherent Market Insights

Contraceptive Pills Market is estimated to be valued at USD 8.12 Bn in 2025 and is expected to reach USD 13.12 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.

The global contraceptive pills market represents a critical segment of the reproductive health industry, encompassing oral contraceptive medications designed to prevent unwanted pregnancies through hormonal regulation mechanisms. These pharmaceutical products, primarily containing synthetic versions of estrogen and progestin hormones, work by suppressing ovulation, altering cervical mucus consistency, and modifying the uterine lining to create multiple barriers against conception.

The market has evolved significantly since the introduction of the first oral contraceptive in the 1960s, transforming from basic hormonal formulations to sophisticated, low-dose combinations that minimize side effects while maintaining efficacy. Modern contraceptive pills are categorized into combination pills containing both estrogen and progestin, and progestin-only pills, each offering distinct advantages for different patient demographics.

The industry serves diverse consumer needs through various formulations including monophasic, biphasic, and triphasic pills, extended-cycle options, and emergency contraceptives. This market operates within a complex ecosystem involving pharmaceutical manufacturers, healthcare providers, regulatory bodies, and end-users, with distribution channels spanning hospitals, clinics, pharmacies, and increasingly, online platforms. The contraceptive pills market continues to drive innovation in reproductive healthcare, addressing evolving consumer preferences for convenience, reduced side effects, and enhanced therapeutic benefits beyond contraception.

Market Dynamics

The global contraceptive pills market experiences robust growth driven by multiple interconnected factors, with increasing awareness about family planning and reproductive health serving as the primary catalyst for market expansion, particularly in developing regions where government initiatives promote contraceptive accessibility and education programs enhance understanding of birth control options.

Rising female workforce participation globally creates demand for reliable contraceptive methods that enable women to plan pregnancies according to career goals, while growing emphasis on women's empowerment and reproductive rights further accelerates adoption rates. Healthcare infrastructure improvements and expanding insurance coverage for contraceptives in many countries facilitate market penetration, supported by continuous product innovations that reduce side effects and improve user experience through lower hormone doses and novel delivery mechanisms.

However, the market faces significant restraints including cultural and religious opposition to contraceptive use in conservative societies, which limits market penetration in certain geographic regions, while safety concerns regarding long-term hormonal contraceptive use, including increased risks of blood clots, cardiovascular complications, and mood disorders, create hesitancy among potential users and healthcare providers.

Stringent regulatory requirements for contraceptive approval processes increase development costs and time-to-market, while the availability of alternative contraceptive methods such as intrauterine devices, implants, and barrier methods intensifies competitive pressure. Significant opportunities lie in underserved emerging markets with rising youth populations, personalized hormone solutions enabled by new technologies, and broader therapeutic uses of contraceptive pills for acne, endometriosis, and PCOS, which expand the total addressable market and unlock new revenue streams.

Key Features of the Study

• This report provides in-depth analysis of the global contraceptive pills market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global contraceptive pills market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc, Bayer AG, Organon & Co, Teva Pharmaceutical Industries Ltd, Mylan NV (Viatris Inc), Johnson & Johnson, Gedeon Richter Plc, Lupin Limited, Cipla Limited, HLL Lifecare Limited, Piramal Enterprises Limited, Sun Pharmaceutical Industries Ltd, Allergan plc (AbbVie Inc), Cadila Healthcare Ltd (Zydus Lifesciences), and Torrent Pharmaceuticals Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global contraceptive pills market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global contraceptive pills market

Market Segmentation

• Pill Category Insights (Revenue, USD Bn, 2020 - 2032)
  • Combined oral contraceptive pills (COCs)
  • Progestin-only pills (POPs/mini-pills)
  • Emergency contraceptive pills (ECPs)
• Hormonal Composition Insights (Revenue, USD Bn, 2020 - 2032)
  • Monophasic Pills
  • Biphasic Pills
  • Triphasic Pills
• Dosage Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • Low-Dose Pills
  • Standard-Dose Pills
  • High-Dose Pills
• Progestin Generation Insights (Revenue, USD Bn, 2020 - 2032)
  • First-Generation Progestin Pills
  • Second-Generation Progestin Pills
  • Third-Generation Progestin Pills
  • Fourth-Generation Progestin Pills
• User Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • 15-19 years
  • 20-29 years
  • 30-39 years
  • 40+ years
• Prescription Status Insights (Revenue, USD Bn, 2020 - 2032)
  • Prescription-Based Pills
  • Over-the-Counter Pills
• Brand Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Generic
  • Branded
• Application Need Insights (Revenue, USD Bn, 2020 - 2032)
  • Birth Control
  • Hormonal Regulation
  • Acne Management
  • Menstrual Cycle Management
• Packaging Format Insights (Revenue, USD Bn, 2020 - 2032)
  • 21-Day Pack
  • 24-Day Pack
  • 28-Day Pack
  • 91-Day Pack
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc
  • Bayer AG
  • Organon & Co
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV (Viatris Inc)
  • Johnson & Johnson
  • Gedeon Richter Plc
  • Lupin Limited
  • Cipla Limited
  • HLL Lifecare Limited
  • Piramal Enterprises Limited
  • Sun Pharmaceutical Industries Ltd
  • Allergan plc (AbbVie Inc)
  • Cadila Healthcare Ltd (Zydus Lifesciences)
  • Torrent Pharmaceuticals Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Contraceptive Pills Market, By Pill Category
  • Global Contraceptive Pills Market, By Hormonal Composition
  • Global Contraceptive Pills Market, By Dosage Strength
  • Global Contraceptive Pills Market, By Progestin Generation
  • Global Contraceptive Pills Market, By User Age Group
  • Global Contraceptive Pills Market, By Prescription Status
  • Global Contraceptive Pills Market, By Brand Type
  • Global Contraceptive Pills Market, By Application Need
  • Global Contraceptive Pills Market, By Packaging Format
  • Global Contraceptive Pills Market, By Distribution Channel
  • Global Contraceptive Pills Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Contraceptive Pills Market, By Pill Category, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Combined oral contraceptive pills (COCs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Progestin-only pills (POPs/mini-pills)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Emergency contraceptive pills (ECPs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Contraceptive Pills Market, By Hormonal Composition, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Monophasic Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biphasic Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Triphasic Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Contraceptive Pills Market, By Dosage Strength, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Low-Dose Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Standard-Dose Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• High-Dose Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Contraceptive Pills Market, By Progestin Generation, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• First-Generation Progestin Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Second-Generation Progestin Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Third-Generation Progestin Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fourth-Generation Progestin Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Contraceptive Pills Market, By User Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 15-19 years
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 20-29 years
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 30-39 years
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 40+ years
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Contraceptive Pills Market, By Prescription Status, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Prescription-Based Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Over-the-Counter Pills
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Contraceptive Pills Market, By Brand Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Branded
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Contraceptive Pills Market, By Application Need, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Birth Control
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hormonal Regulation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Acne Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Menstrual Cycle Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Contraceptive Pills Market, By Packaging Format, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 21-Day Pack
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 24-Day Pack
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 28-Day Pack
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 91-Day Pack
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Contraceptive Pills Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

14. Global Contraceptive Pills Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Pill Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Hormonal Composition, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Progestin Generation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By User Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application Need, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Packaging Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Pill Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Hormonal Composition, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Progestin Generation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By User Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application Need, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Packaging Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Pill Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Hormonal Composition, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Progestin Generation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By User Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application Need, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Packaging Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Pill Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Hormonal Composition, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Progestin Generation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By User Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application Need, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Packaging Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Pill Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Hormonal Composition, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Progestin Generation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By User Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application Need, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Packaging Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Pill Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Hormonal Composition, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Progestin Generation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By User Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application Need, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Packaging Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

15. Competitive Landscape

• Pfizer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Organon & Co
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan NV (Viatris Inc)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gedeon Richter Plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• HLL Lifecare Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Piramal Enterprises Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Allergan plc (AbbVie Inc)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cadila Healthcare Ltd (Zydus Lifesciences)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Torrent Pharmaceuticals Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

16. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

17. References and Research Methodology

• References
• Research Methodology
• About us